Rochelle Bagatell, M.D.

faculty photo
Professor of Pediatrics (Oncology) at the Children's Hospital of Philadelphia
Department: Pediatrics

Contact information
The Children's Hospital of Philadelphia
The Hub for Clinical Collaboration, room 3524
3500 Civic Center Boulevard
Philadelphia, PA 19104
Office: 267-426-9737
Education:
BA (History)
Brown University, 1987.
M.D.
University of Arizona, 1993.
Permanent link
 
> Perelman School of Medicine   > Faculty   > Details

Selected Publications

Bacchus MK, Anderson DS, Berko ER, States LJ, Bagatell R, Hopkins S, Batra V: Neuroblastic Tumor Recurrence Associated with Opsoclonus Myoclonus Ataxia Syndrome Relapse a Decade after Initial Resection and Treatment. J Pediatr Hematol Oncol. 45(3): 152-154, January 2023 Notes: Accepted

Pinto N, Naranjo A, Ding X, Zhang FF, Hibbitts E, Kennedy R, Pfau R, Tibbetts R, Wong-Michalak S, Craig DW, Manojlovic Z, Hogarty MD, Kreissman S, Bagatell R, Irwin MS, Park JR, Asgharzadeh S: Impact of Genomic and Clinical Factors on Outcome of Children>18 months of Age with INSS Stage 3 Neuroblastoma with Unfavorable Histology without MYCN Amplification. Clinical Cancer Research 2023.

Erbe AK, Diccianni MB, Mody R, Naranjo A, Zhang FF, Birstler J, Kim K, Feils AS, Hung J-T, London WB, Shulkin BL, Matthew V, Parisi MT, Servaes S, Asgharzadeh S, Maris JM, Park JR, Yu AL, Sondel PM, Bagatell R: KIR/KIR-Ligand Genotypes and Clinical Outcomes Following Chemo-Immunotherapy in Patients with Relapsed or Refractory Neuroblastoma. A report from the Children's Oncology Group. Accepted for Publication in Journal of Immunotherapy of Cancer. 2023.

Lerman BJ, Li Y, Carlowicz C, Granger MM, Cash T, Sadanand A, Somers K, Ranavaya A, Weiss BD, Choe M, Foster JH, Pinto N, Morgenstern DA, Rafael MS, Streby KA, Zeno RN, Mody R, Yazdani S, Desai AV, Macy ME, Shusterman S, Federico SM, Bagatell R.: Progression-Free Survival and Patterns of Response in Patients with Relapsed High-Risk Neuroblastoma Treated with Irinotecan/Temozolomide/Dinutuximab/GM-CSF. Journal of Clinical Oncology 41(3): 508-516, 2023.

Desai AV, Gilman AL, Ozkaynak MF, Naranjo A, London WB, Tenney SC, Diccianni M, Hank JA, Parisi, MT, Shulkin BL, Smith M, Moscow JA, Shimada H, Matthay KK, Cohn SL, Maris JM, Bagatell R, Sondel PM, Park JR, Yu AL: Outcomes Following Anti-GD2 Antibody-Based Post-Consolidation Therapy After Cessation of Randomization on ANBL0032: A Report from the Children’s Oncology Group. Accepted for publication in the Journal of Clinical Oncology April 2022.

Church AJ, Corson LB, Kao P-C, Imamovic-Tuco A, Reidy D, Doan D, Kang W, Pinto N, Maese L, Laetsch T, Kim A, Colace S, Macy M, Applebaum M, Bagatell R, Sabnis A, Weiser D, Glade-Bender J, Homans A, Hipps J, Lo Y-C, Strand G, Lee L, Pinches RS, De La Vega LL, Harden M, Lennon N, Choi S, Comeau H, Harris M, Forrest S, Clinton C, Crompton B, Kamihara J, MacConnaill L, Volchenboum S, Lindeman N, Van Allen E, DuBois S, London W, Janeway K, Harris H, Manning D, Al-Ibraheemi A, Li Yvonne, Gupta H, Cherniack A: Molecular Profiling Identifies Targeted Therapy Opportunities in Pediatric Solid Cancer. Accepted for publication in Nature Medicine 28(8): 1581-1589, April 2022.

Desai AV, Applebaum MA, Karr A, Oppong A, Yuan C, Berg KR, MacQuarrie K, Sokol E, Hall A, Pinto N, Wolfe L, Mody R, Shusterman S, Smith VR, Foster JH, Nassin M, Labelle J, Bagatell R, Cohn SL: Efficacy of Post-Induction Therapy for High-Risk Neuroblastoma Patients with End-Induction Residual Disease. Accepted for publication in Cancer 128(15): 2967-2977, January 2022.

Nader J, Bourgeois F, Bagatell R, Moreno L, Pearson ADJ, Dubois SG: Systematic Review of Clinical Drug Development Activities for Neuroblastoma from 2011-2020. Pediatric Blood Cancer 2022.

Desai AV, Gilman AL, Ozkayank MF, Naranjo A, London WB, Tenney SC, Diccianni M, Hank JA, Parisi MT, Shulkin BL, Smith M, Moscow JA, Shimada H, Matthay KK, Cohn SL, Maris JM, Bagatell R, Sondel PM, Park JR, Yu Al.: Outcomes Following Anti-GC2 Antibody-Based Post-Consolidation Therapy After Cessation of Randomization on ANBL0032. Children's Oncology Group. Journal of Clinical Oncology 40(35): 4107-4118, 2022.

Xu F, Viaene AN, Ruiz J, Schubert J, Wu J, Chen J, Cao K, Fu W, Bagatell R, Fan Z, Long A, Pagliaroli L, Zhong Y, Kreiger PA, Surrey L, WeRtheim GB, Cole KA, Li MM, Santi M, Storm PB: Novel ATXN1/ATXNIL:NUTM2A Fusions Identified in Aggressive Infant Sarcomas with Gene Expression and Methylation Patterns Similar to CIC-rearranged Sarcoma. Acta Neuropathologica Communications 10(1): 102, 2022.

back to top
Last updated: 04/27/2023
The Trustees of the University of Pennsylvania